Issue 95, 2022

Oridonin acts as a novel senolytic by targeting glutathione S-transferases to activate the ROS-p38 signaling axis in senescent cells

Abstract

Most of the known senolytics are anti-cancer drugs or their derivative molecules. However, senolytics derived from the active ingredients of traditional Chinese medicine (TCM) are rarely reported. Here, we identified oridonin as a novel senolytic and further revealed that it might target a class of glutathione S-transferases to activate ROS-p38 signaling and induce apoptosis in senescent cells.

Graphical abstract: Oridonin acts as a novel senolytic by targeting glutathione S-transferases to activate the ROS-p38 signaling axis in senescent cells

Supplementary files

Article information

Article type
Communication
Submitted
26 Sep 2022
Accepted
08 Oct 2022
First published
19 Oct 2022

Chem. Commun., 2022,58, 13250-13253

Oridonin acts as a novel senolytic by targeting glutathione S-transferases to activate the ROS-p38 signaling axis in senescent cells

Y. Zhang, Q. Zhang, Z. Chu, L. Chen, J. Chen, Y. Yang, H. Tang, G. Cheng, A. Ma, Y. Zhang, C. Wang, P. Gao, F. Xia, Q. Guo, Q. Shi, G. Han, J. Wang and Y. Zhu, Chem. Commun., 2022, 58, 13250 DOI: 10.1039/D2CC05278D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements